InnoCan Pharma Corporation (INNO.CN)
| Previous Close | 0.2750 |
| Open | 0.2800 |
| Bid | 0.2600 x N/A |
| Ask | 0.2750 x N/A |
| Day's Range | 0.2600 - 0.2800 |
| 52 Week Range | 0.1800 - 0.5200 |
| Volume | |
| Avg. Volume | 88,098 |
| Market Cap | 75.778M |
| Beta (5Y Monthly) | 3.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupInnocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
- CNW Group
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelin
- CNW Group
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the "Offering Price") for aggregate gross proceeds of $1,988,210.
